Physician profile
Daniel Oswari
NPI 1265506489
$774.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $173.81 | 2019 | |
| Lilly USA, LLC | $101.57 | 2019 | |
| Glaxosmithkline, LLC. | $81.12 | 2019 | |
| Novo Nordisk INC | $79.42 | 2019 | |
| Merck Sharp & Dohme LLC | $65.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.95 | 2019 | |
| Pfizer INC. | $39.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $38.04 | 2019 | |
| Genentech USA, INC. | $37.38 | 2019 | |
| Allergan, INC. | $36.73 | 2019 | |
| Pharming Healthcare, INC. | $27.28 | 2019 | |
| Amarin Pharma, INC. | $26.21 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Oswari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.